

**FILED**

SEP 28 2007

NE

Sep. 28, 2007

MICHAEL W. DOBBINS  
CLERK, U.S. DISTRICT COURT

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF ILLINOIS  
EASTERN DIVISION

JH

ELI LILLY AND COMPANY,

Plaintiff,

v.

AUROBINDO PHARMA LTD.

Defendant.

07CV 5488  
JUDGE HIBBLER  
MAGISTRATE JUDGE COX

**COMPLAINT**

Plaintiff Eli Lilly and Company, (hereinafter "Lilly") for its Complaint against Defendant Aurobindo Pharma Ltd. (hereinafter "Aurobindo"), hereby alleges as follows:

**Nature of the Action**

1. This is a civil action for the infringement of United States Patent No. 5,658,590 ("the '590 patent"). This action relates to an Abbreviated New Drug Application ("ANDA") filed by Aurobindo with the United States Food and Drug Administration ("FDA") for approval to market generic versions of Lilly's Strattera<sup>®</sup> drug products. This action arises under the patent laws of the United States, 35 U.S.C. § 100, *et seq.*

**Parties**

2. Plaintiff Eli Lilly and Company is an Indiana corporation having a principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285.

3. Upon information and belief, Defendant Aurobindo is a corporation organized under the laws of India, having a principal place of business at Plot # 2, Maitri Vihar, Amcerpet, Hyderabad – 500 038, Andhra Pradesh, India.

**Jurisdiction and Venue**

4. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

5. This Court has personal jurisdiction over Aurobindo by virtue of its consent to jurisdiction here.

6. Venue is proper in this judicial district pursuant to, *inter alia*, 28 U.S.C. §§ 1391(b) and/or 1400(b).

**Plaintiff's Strattera<sup>®</sup> Products and Related Patent**

7. On August 19, 1997, the '590 patent, titled "Treatment of Attention-Deficit/Hyperactivity Disorder," was duly and legally issued to John H. Heiligenstein and Gary D. Tollefson and assigned to Lilly. A true and correct copy of the '590 patent is attached hereto as Exhibit A. The '590 patent claims methods of treating attention-deficit/hyperactivity disorder with tomoxetine. Tomoxetine is now known as atomoxetine. The claims of the '590 patent are valid and enforceable. The '590 patent expires on November 26, 2016.

8. Strattera<sup>®</sup> is the brand name for the commercial formulation of atomoxetine hydrochloride developed, manufactured, and sold by Lilly. Lilly submitted a New Drug Application to the FDA for Strattera<sup>®</sup> Capsules for the treatment of attention-deficit/hyperactivity disorder (NDA No. 21-411). NDA No. 21-411 was approved by the FDA on or about November 26, 2002, for Strattera<sup>®</sup> Capsules in strengths of Eq 10 mg, 18 mg, 25 mg, 40 mg, and 60 mg. Strattera<sup>®</sup> Capsules in strengths of Eq 80 mg and 100 mg were approved on or about February 14, 2005.

9. The Food And Drug Administration Center For Drug Evaluation And Research Approved Drug Products With Therapeutic Equivalence Evaluations (the "Orange Book") lists

the '590 patent for each of the strengths of Strattera<sup>®</sup> approved by the FDA under NDA No. 21-411.

10. Pursuant to 21 U.S.C. § 355a, Lilly is entitled to a six-month period of pediatric exclusivity for Strattera<sup>®</sup> beyond the date of expiration of the '590 patent.

#### **AUROBINDO'S ANDA FILING**

11. By letter dated August 14, 2007 (the "Aurobindo Notice Letter"), Aurobindo notified Lilly that Aurobindo had submitted ANDA No. 79-016 to the FDA under § 505(j) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(j) (the "Aurobindo ANDA"). On information and belief, the Aurobindo ANDA seeks approval to engage in the commercial manufacture, use or sale of generic Atomoxetine Hydrochloride Capsules, Eq 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg Atomoxetine (collectively the "Aurobindo Atomoxetine Capsules") — generic versions of each of the FDA-approved Strattera<sup>®</sup> Capsule strengths — before the expiration date of the '590 patent.

12. By filing the Aurobindo ANDA, Aurobindo has necessarily represented to the FDA that the Aurobindo Atomoxetine Capsules have the same active ingredient as Strattera<sup>®</sup>, have the same route of administration, dosage form, and strengths as Strattera<sup>®</sup>, are bioequivalent to Strattera<sup>®</sup>, and have the same or substantially the same proposed labeling and use as Strattera<sup>®</sup>.

13. In the Aurobindo Notice Letter, Aurobindo notified Lilly that the Aurobindo ANDA contains a paragraph IV certification with respect to the '590 patent. Aurobindo attached to the Aurobindo Notice Letter a statement asserting its opinion that the '590 patent is invalid, unenforceable, or will not be infringed by the Aurobindo Atomoxetine Capsules.

14. This action is being brought before the expiration of forty-five days from the date Lilly received the Aurobindo Notice Letter, which Lilly received no earlier than August 15, 2007.

### **COUNT I**

#### **Infringement of the '590 Patent**

15. Lilly incorporates the preceding paragraphs as if fully set forth herein.

16. Aurobindo's submission of the Aurobindo ANDA to obtain approval to engage in the commercial manufacture, use, offer to sell, or sale of the Aurobindo Atomoxetine Capsules prior to the expiration of the '590 patent constitutes infringement of one or more of the valid claims of the '590 patent under 35 U.S.C. § 271(e)(2)(A).

17. Aurobindo's commercial manufacture, use, offer to sell, sale, or importation of the Aurobindo Atomoxetine Capsules for the treatment of attention-deficit/hyperactivity disorder prior to the expiration of the '590 patent, and its inducement of or contribution to such conduct, would further infringe the '590 patent under 35 U.S.C. §§ 271(a), (b) and/or (c). Aurobindo's filing of the Aurobindo ANDA and its intention to engage in the commercial manufacture, use, offer to sell, sale, or importation of the Aurobindo Atomoxetine Capsules for the treatment of attention-deficit/hyperactivity disorder, and its intention to induce such conduct upon receiving FDA approval, create an actual case or controversy with respect to infringement of the '590 patent.

18. Upon FDA approval of the Aurobindo ANDA, Aurobindo will infringe the '590 patent by making, using, offering to sell, selling, or importing the Aurobindo Atomoxetine Capsules in the United States for the treatment of attention-deficit/hyperactivity disorder, and by actively inducing and/or contributing to infringement by others, unless enjoined by this Court.

19. Lilly will be irreparably harmed if Aurobindo's infringement is not enjoined.

Lilly does not have an adequate remedy at law.

**Prayer for Relief**


**WHEREFORE**, Lilly prays that this Court grant the following relief:

- A. A declaration that the '590 patent is valid and enforceable;
- B. A declaration that a claim or claims of the '590 patent are infringed by the manufacture, use, sale, offer for sale or importation of the Aurobindo Atomoxetine Capsules, that Aurobindo's submission of the Aurobindo ANDA is an act of infringement of the '590 patent, that making, using, offering to sell, selling, or importing the Aurobindo Atomoxetine Capsules for the treatment of attention-deficit/hyperactivity disorder by Aurobindo, and its inducement of and/or contribution to such conduct by others, will infringe the '590 patent;
- C. An Order providing that the effective date of any approval of the Aurobindo ANDA shall be a date which is not earlier than six months after the expiration of the '590 patent;
- D. An Order permanently enjoining Aurobindo and its affiliates and subsidiaries, and each of their officers, agents, servants, and employees, from making, using, offering to sell, selling, or importing the Aurobindo Atomoxetine Capsules and from inducing or contributing to such conduct by others, until after six months after the expiration of the '590 patent;
- E. An Order that damages or other monetary relief be awarded to Lilly if Aurobindo engages in the commercial manufacture, use, offer to sell, sale, or importation of the Aurobindo Atomoxetine Capsules, or in inducing or contributing to such conduct by others, prior to six months after the expiration of the '590 patent, and that any such damages or monetary relief be trebled and awarded to Lilly with prejudgment interest;

F. Reasonable attorneys fees, filing fees, and reasonable costs of suit incurred by Lilly in this action; and

G. Such further and other relief as this Court deems proper and just.

Respectfully submitted,



Daniel P. Albers  
Jonathan P. Froemel  
Barnes & Thornburg LLP  
One N. Wacker Drive, Suite 4400  
Chicago, IL 60606  
(312) 357-1313

Attorneys for Plaintiffs  
Eli Lilly and Company

*Of counsel:*

William F. Lee, Esq.  
Richard W. O'Neill, Esq.  
WILMER, CUTLER, PICKERING,  
HALE AND DORR LLP  
60 State Street  
Boston, MA 02109  
Phone: (617) 526-6000  
Fax: (617) 526-5000

David B. Bassett, Esq.  
WILMER, CUTLER, PICKERING,  
HALE AND DORR LLP  
399 Park Avenue  
New York, New York 10022  
Phone: (212) 230-8800  
Fax: (212) 230-8888

Henry N. Wixon, Esq.  
WILMER, CUTLER, PICKERING,  
HALE AND DORR LLP  
1875 Pennsylvania Avenue, N.W.  
Washington, DC 20006  
Phone: (202) 663-6000  
Fax: (202) 663-6363

Attorneys for Plaintiffs

Dated: September 28, 2007  
CHDS01 421279v1